Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr0.99
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr225.31M
Enterprise Valuekr71.98
Total Cash (Recent Filing)kr110.74M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding320,491,640
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthIsofol's negligible reported debt materially reduces financing-related insolvency risk and preserves strategic optionality. For a clinical-stage biotech, low leverage supports the ability to raise incremental capital on better terms, sustain R&D investment, and survive longer clinical timelines without immediate refinancing pressure.
Improving Free Cash Outflow (TTM)A marked reduction in free cash outflow to roughly -3.6M TTM indicates operational efficiency gains and extended runway versus prior years. This durable improvement lessens near-term dilution pressure, buys time for clinical milestones, and reduces frequency and magnitude of capital raises if maintained over the next several quarters.
Proprietary Oncology Asset (Arfolitixorin)Isofol's focus on arfolitixorin targets established 5-FU chemotherapy regimens, addressing a large colorectal cancer treatment market. A proprietary, differentiated compound that enhances standard chemo can create durable licensing or commercialization opportunities if clinical data validates benefit, underpinning long-term strategic value.
Bears Say
No Revenue BaseThe absence of recurring revenue is a fundamental weakness: with revenues at zero in recent periods, Isofol cannot self-fund development or operations. This structural shortfall forces reliance on equity or debt financing, increasing dilution risk and making long-term planning dependent on successful capital raises or milestone deals.
Capital Erosion / Declining EquityMaterial decline in shareholder equity reflects repeated losses and potential dilution, reducing the company's capital cushion. Persistent negative returns on equity signal that invested capital has not produced profits, constraining future investment capacity and increasing vulnerability to unfavorable financing terms or shareholder dilution ahead of commercialization.
Sustained Operating Cash BurnA sustained operating cash outflow near -55.6M TTM demonstrates high cash consumption typical of clinical development but remains a durable risk. Continued high burn without revenue means ongoing financing needs, elevating execution risk if capital markets tighten or if clinical setbacks delay value-creating milestones.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr0.99 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr225.31M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Aug 25, 2026 which is in 30 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on May 19, 2026. The company reported -kr0.054 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.636%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―